Skip to main content
Premium Trial:

Request an Annual Quote

Thomson Reuters, CHDI Partner on Tools for Huntington's Disease

NEW YORK (GenomeWeb News) – Thomson Reuters' Intellectual Property & Science business announced a deal with the CHDI Foundation to develop systems biology tools for Huntington's disease.

The terms of the collaboration, announced on Thursday, include the reconstruction and analysis of causal networks that underlie HD mechanisms, and building a comprehensive collection of HD pathology pathway maps.

One goal of the deal, called the MetaMiner Partnership, is to identify disease mechanisms by network analysis of gene expression data in patients who have different numbers of CAG repeats in the huntingtin gene. The number of CAG repeats can predict the age of disease onset, Thomson Reuters said.

It added that in work carried out for MetaMiner for HD, a program focusing on HD pathway reconstruction, it and collaborators have generated 15 specific HD pathway maps and its partnership with CHDI will build on that effort. Once completed, images of the new HD pathway maps will be available on CHDI's website and through Thomson Reuters' MetaCore analysis tool suite.

Financial and other terms of the deal were not disclosed.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.